Vadadustat-13C6

Vadadustat-13C6 (PG-1016548-13C6) is 13C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor[1]. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo[1][2].

Product Specifications

Product Name Alternative

PG-1016548-13C6; AKB-6548-13C6

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C(CNC(C1=NC=C(C=C1O)[13C]2=[13CH][13CH]=[13CH][13C](Cl)=[13CH]2)=O)O

Molecular Formula

C8 13C6H11ClN2O4

Molecular Weight

312.66

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Pergola PE, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90 (5) :1115-1122.|[3]Gupta N, et al. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Feb 24. pii: S0272-6386 (17) 30110-5.